The U.S. Food and Drug Administration has granted approval to Johnson & Johnson's oral medication for psoriasis, the company announced on Wednesday. Branded as Icotyde, the pill is cleared for the treatment of moderate-to-severe plaque psoriasis in adults and in pediatric patients aged 12 years and older who weigh at least 40 kg.
The approval provides a non-injectable treatment option for patients with the chronic autoimmune condition that produces itchy, scaly, and inflamed skin patches. J&J has positioned Icotyde as a once-daily oral therapy that could simplify treatment for patients seeking ease of use, skin clearance, and a favorable safety profile.
Icotyde, chemically known as icotrokinra, was developed in partnership with Protagonist Therapeutics. The medication works by blocking IL-23, a protein involved in inflammatory responses - the same biological target as some existing therapies. Like AbbVie's Skyrizi and J&J's own Tremfya, Icotyde targets IL-23 pathways to reduce inflammation.
In two late-stage head-to-head trials, Icotyde demonstrated superior skin clearance compared with Bristol Myers Squibb's oral treatment Sotyktu. Wall Street analysts have described Icotyde as having "blockbuster potential" given its safety profile and oral, once-daily dosing, with expectations that it could capture meaningful market share.
David Lee, J&J's global head of immunology, said patients have been seeking complete skin clearance, a favorable safety profile, and the simplicity of a once-daily pill. "We see Icotyde as becoming the first-line systemic therapy for psoriasis patients," he said.
The new oral option will compete directly with Bristol Myers Squibb's Sotyktu and AbbVie's Skyrizi. The approval also comes as J&J's established injectable Stelara is facing mounting competition from lower-cost copycat drugs, a dynamic that has encouraged the company to broaden its portfolio.
J&J is continuing studies of icotrokinra in additional inflammatory conditions. The company is evaluating the drug for ulcerative colitis, psoriatic arthritis, and Crohn's disease, though those indications remain under investigation and have not been approved.
J&J has not yet provided details on pricing or the timeline for availability following the regulatory decision. The absence of immediate information on cost and market rollout leaves questions about uptake and commercial dynamics unanswered for now.
Sectors impacted: Pharmaceuticals, biotechnology, healthcare services and specialty therapeutics.